West Pharmaceutical Services (WST) revenue breakdown
By segment, Proprietary Products is the largest at 81% of fiscal 2025 revenue, growing 9% a year over 9 years.
By region, United States is the largest at 43% of fiscal 2025 revenue; Ireland grew fastest, 16% a year over 8 years.
Revenue by segment
Fiscal years, as West Pharmaceutical Services reports them in its 10-K filings; fiscal 2025 total $3.1B.
| Segments | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Proprietary Products | $1.2B | $1.2B | $1.3B | $1.4B | $1.6B | $2.3B | $2.4B | $2.4B | $2.3B | $2.5B | 81% |
| Contract-Manufactured Products | $320M | $362M | $409M | $442M | $499M | $515M | $480M | $552M | $559M | $582M | 19% |
| Corporate and Eliminations | -$1M | -$300,000 | — | — | — | — | — | — | — | — | — |
Revenue by region
Fiscal years, as West Pharmaceutical Services reports them in its 10-K filings; fiscal 2025 total $3.1B.
| Regions | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $738M | $735M | $766M | $815M | $976M | $1.2B | $1.3B | $1.2B | $1.2B | $1.3B | 43% |
| Other European countries | $268M | $201M | $230M | $251M | $237M | $341M | $359M | $388M | $386M | $451M | 15% |
| Germany | $201M | $226M | $236M | $236M | $282M | $474M | $399M | $406M | $372M | $380M | 12% |
| Other | $186M | $194M | $202M | $213M | $254M | $357M | $364M | $348M | $339M | $353M | 11% |
| Ireland | — | $100M | $138M | $174M | $226M | $248M | $240M | $286M | $323M | $333M | 11% |
| France | $116M | $143M | $145M | $151M | $173M | $213M | $238M | $283M | $242M | $227M | 7% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for WST.
Open WST in InvestinglyQuestions
Where does West Pharmaceutical Services make its money?
In fiscal 2025, by segment: Proprietary Products $2.5B, Contract-Manufactured Products $582M.
From West Pharmaceutical Services's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.